LTC1663240I2 - Pirimidino deriniai, turintys nnrti su rt slopikliais - Google Patents

Pirimidino deriniai, turintys nnrti su rt slopikliais

Info

Publication number
LTC1663240I2
LTC1663240I2 LTPA2015035C LTPA2016044C LTC1663240I2 LT C1663240 I2 LTC1663240 I2 LT C1663240I2 LT PA2015035 C LTPA2015035 C LT PA2015035C LT PA2016044 C LTPA2016044 C LT PA2016044C LT C1663240 I2 LTC1663240 I2 LT C1663240I2
Authority
LT
Lithuania
Prior art keywords
pyrimidine
inhibitors
combinations containing
nnrti
containing nnrti
Prior art date
Application number
LTPA2015035C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC1663240(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of LTPA2016044I1 publication Critical patent/LTPA2016044I1/lt
Publication of LTC1663240I2 publication Critical patent/LTC1663240I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTPA2015035C 2003-09-03 2016-12-20 Pirimidino deriniai, turintys nnrti su rt slopikliais LTC1663240I2 (lt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP04787096.9A EP1663240B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (2)

Publication Number Publication Date
LTPA2016044I1 LTPA2016044I1 (lt) 2017-01-10
LTC1663240I2 true LTC1663240I2 (lt) 2022-05-25

Family

ID=34280181

Family Applications (2)

Application Number Title Priority Date Filing Date
LTPA2015035C LTC1663240I2 (lt) 2003-09-03 2016-12-20 Pirimidino deriniai, turintys nnrti su rt slopikliais
LTPA2016045C LTPA2016045I1 (lt) 2003-09-03 2016-12-20 Pirimidino deriniai, turintys NNRTI su RT slopikliais

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2016045C LTPA2016045I1 (lt) 2003-09-03 2016-12-20 Pirimidino deriniai, turintys NNRTI su RT slopikliais

Country Status (24)

Country Link
US (9) US20080200435A1 (OSRAM)
EP (1) EP1663240B2 (OSRAM)
JP (3) JP5507791B2 (OSRAM)
KR (1) KR20060090658A (OSRAM)
CN (1) CN101060844B (OSRAM)
AP (1) AP2109A (OSRAM)
AU (5) AU2004268390B2 (OSRAM)
BE (1) BE2015C053I2 (OSRAM)
CA (1) CA2537095C (OSRAM)
CY (5) CY2015040I2 (OSRAM)
FI (1) FI1663240T4 (OSRAM)
FR (5) FR15C0072I2 (OSRAM)
HR (1) HRP20150798T4 (OSRAM)
HU (5) HUS1500053I1 (OSRAM)
IL (2) IL173438A (OSRAM)
LT (2) LTC1663240I2 (OSRAM)
LU (3) LU92853I2 (OSRAM)
MX (1) MXPA06002437A (OSRAM)
MY (1) MY169670A (OSRAM)
NL (2) NL300781I2 (OSRAM)
NO (6) NO334877B1 (OSRAM)
NZ (1) NZ545306A (OSRAM)
PL (1) PL1663240T5 (OSRAM)
WO (1) WO2005021001A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
JP4822707B2 (ja) 2002-08-09 2011-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの製造方法
DE602004014470D1 (de) 2003-01-14 2008-07-31 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
SI1632232T1 (sl) * 2004-09-02 2011-09-30 Janssen Pharmaceutica Nv Sol 4((4((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino) benzonitrila
HRP20120499T1 (hr) * 2004-09-02 2012-07-31 Janssen@Pharmaceutica@NV Fumarat cijanoetenil dimetilfenil amino pirimidinil amino benzonitrila
UA92469C2 (en) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
PL1632232T6 (pl) * 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CA2633603C (en) * 2005-12-14 2016-09-13 Cipla Limited Pharmaceutical combination
DK1981506T6 (da) * 2006-01-20 2021-06-14 Janssen Sciences Ireland Unlimited Co Langtidsbehandling af hiv-infektion med tcm278
US9044509B2 (en) * 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
DK2234620T3 (en) * 2008-01-03 2016-06-06 Université D'aix-Marseille Triple therapy used for treatment of an hiv-infected patient
NZ593950A (en) * 2008-12-24 2013-08-30 Janssen R & D Ireland Implantable devices for treating hiv
EP2515877B1 (en) 2009-12-21 2016-08-10 Janssen Sciences Ireland UC Degradable removable implant for the sustained release of an active compound
ES2670811T3 (es) 2010-01-27 2018-06-01 Viiv Healthcare Company Terapia antivírica
TWI556840B (zh) 2010-11-19 2016-11-11 吉李德科學股份有限公司 治療用組成物
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2013038425A1 (en) * 2011-09-16 2013-03-21 Hetero Research Foundation Rilpivirine hydrochloride
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
JP6621933B2 (ja) 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
SMT202400060T1 (it) 2016-10-24 2024-03-13 Janssen Sciences Ireland Unlimited Co Composizioni dispersibili
US20210128554A1 (en) * 2016-12-23 2021-05-06 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
BR112019021918A2 (pt) * 2017-04-18 2020-05-26 Cipla Limited Terapia de combinação para uso no tratamento de infecções retroviriais
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
AU2020391004A1 (en) 2019-11-29 2022-04-07 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
EP0489181B1 (en) 1990-07-19 1996-10-02 Otsuka Pharmaceutical Co., Ltd. Solid preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5837747A (en) * 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
DK0639971T3 (da) 1992-05-13 2000-03-20 Wellcome Found Terapeutiske kombinationer
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2001021154A2 (en) 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) * 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
MXPA02009534A (es) 2000-03-30 2003-05-14 Squibb Bristol Myers Co Granulos de liberacion sostenida que contienen estavudina.
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
US20040058956A1 (en) 2000-12-11 2004-03-25 Yohko Akiyama Pharmaceutical composition having an improved water solubility
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JP2005511629A (ja) 2001-11-20 2005-04-28 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続作用生成物送達用組成物
JP4822707B2 (ja) 2002-08-09 2011-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの製造方法
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
ES2286471T3 (es) 2002-11-08 2007-12-01 Glaxo Group Limited Composiciones farmaceuticas antivirales.
US7608726B2 (en) 2002-11-15 2009-10-27 Tibotec Pharmaceuticals Ltd. Substituted indolepyridinium as anti-infective compounds
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AP2065A (en) 2003-02-07 2009-11-26 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
AR049297A1 (es) 2004-06-08 2006-07-12 Vertex Pharma Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
SI1632232T1 (sl) 2004-09-02 2011-09-30 Janssen Pharmaceutica Nv Sol 4((4((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino) benzonitrila
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
CA2587710C (en) 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
EP1872390A2 (en) * 2005-04-11 2008-01-02 The Board of Trustees of the Leland Stanford Junior University Multi-layer structure having a predetermined layer pattern including an agent
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US20090142401A1 (en) 2005-06-07 2009-06-04 Leah Elizabeth Appel Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
CN101272769B (zh) 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
DK1981506T6 (da) 2006-01-20 2021-06-14 Janssen Sciences Ireland Unlimited Co Langtidsbehandling af hiv-infektion med tcm278
PE20080210A1 (es) 2006-06-23 2008-04-11 Tibotec Pharm Ltd Suspensiones acuosas de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrilo (tmc278)
US20080081064A1 (en) * 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2175857B1 (en) 2007-07-12 2013-09-11 Janssen R&D Ireland Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
WO2010047819A1 (en) * 2008-10-24 2010-04-29 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives

Also Published As

Publication number Publication date
AU2016210733A1 (en) 2016-08-25
FR15C0071I1 (OSRAM) 2015-04-12
AU2016210733B2 (en) 2018-11-08
US20180228800A1 (en) 2018-08-16
AP2109A (en) 2010-02-26
NO2014030I2 (no) 2014-12-18
LU92854I2 (fr) 2015-12-21
LU92855I2 (fr) 2015-12-21
CY2015038I2 (el) 2016-08-31
CY2016048I2 (el) 2017-07-12
NO2016026I1 (no) 2016-12-20
AU2019200813A1 (en) 2019-02-28
FI1663240T4 (fi) 2023-04-25
NO2014030I1 (no) 2015-01-05
US20140349971A1 (en) 2014-11-27
NL300781I1 (OSRAM) 2016-04-19
JP2012051915A (ja) 2012-03-15
CY2015040I1 (el) 2016-08-31
JP2007520443A (ja) 2007-07-26
JP5820045B2 (ja) 2015-11-24
IL213104A (en) 2016-02-29
NO2016025I1 (OSRAM) 2016-12-20
NO2014032I2 (no) 2014-12-18
IL173438A (en) 2012-03-29
AP2006003551A0 (en) 2006-04-30
AU2011201123B2 (en) 2013-10-10
WO2005021001A1 (en) 2005-03-10
NZ545306A (en) 2009-11-27
CN101060844A (zh) 2007-10-24
FR15C0071I2 (fr) 2016-02-12
HUS1600059I1 (hu) 2017-02-28
MY169670A (en) 2019-05-08
BE2015C053I2 (OSRAM) 2023-12-14
HUS1500053I1 (hu) 2016-03-29
CN101060844B (zh) 2012-01-04
US20150283135A1 (en) 2015-10-08
US8841310B2 (en) 2014-09-23
US20170100398A1 (en) 2017-04-13
US20200171027A1 (en) 2020-06-04
US20220008417A1 (en) 2022-01-13
NL300768I2 (nl) 2023-08-09
AU2014203484A1 (en) 2014-07-17
AU2011201123A1 (en) 2011-04-07
HUS1600058I1 (hu) 2017-02-28
JP2015044839A (ja) 2015-03-12
CY2015040I2 (el) 2016-08-31
CY2016049I1 (el) 2017-07-12
EP1663240A1 (en) 2006-06-07
LU92853I2 (fr) 2015-12-21
AU2004268390A1 (en) 2005-03-10
US20100029591A1 (en) 2010-02-04
CY2015039I2 (el) 2016-08-31
FR16C1022I1 (fr) 2017-02-03
FR15C0073I1 (OSRAM) 2015-04-12
IL213104A0 (en) 2011-07-31
CY2016048I1 (el) 2017-07-12
IL173438A0 (en) 2006-06-11
CA2537095A1 (en) 2005-03-10
NL300768I1 (OSRAM) 2015-12-16
NL300781I2 (OSRAM) 2016-04-19
US20080200435A1 (en) 2008-08-21
FR16C1024I1 (fr) 2017-02-03
MXPA06002437A (es) 2006-06-20
HRP20150798T1 (hr) 2015-09-11
NO334877B1 (no) 2014-06-23
CY2015038I1 (el) 2016-08-31
HUS1500052I1 (hu) 2016-03-29
NO20061374L (no) 2006-03-27
NO2014032I1 (no) 2015-01-05
JP5507791B2 (ja) 2014-05-28
PL1663240T5 (pl) 2024-02-26
HK1092698A1 (en) 2007-02-16
AU2014203484B2 (en) 2016-09-29
EP1663240B1 (en) 2015-04-22
HUS1500054I1 (hu) 2016-03-29
LTPA2016045I1 (lt) 2017-01-10
NO2014031I2 (no) 2014-12-18
PL1663240T3 (pl) 2015-10-30
KR20060090658A (ko) 2006-08-14
US20190216807A1 (en) 2019-07-18
EP1663240B2 (en) 2023-03-01
HRP20150798T4 (hr) 2023-06-09
CY2015039I1 (el) 2016-08-31
FR15C0073I2 (fr) 2016-02-12
CA2537095C (en) 2012-05-29
AU2004268390B2 (en) 2011-03-31
FR15C0072I2 (fr) 2019-05-17
LTPA2016044I1 (lt) 2017-01-10
NO2014031I1 (no) 2015-01-05
FR15C0072I1 (OSRAM) 2015-04-12
CY2016049I2 (el) 2017-07-12

Similar Documents

Publication Publication Date Title
LTC1663240I2 (lt) Pirimidino deriniai, turintys nnrti su rt slopikliais
NL2000323A1 (nl) Pyrimidine-derivaten.
DK1761505T3 (da) Pyrimidin-urinstof-derivater som kinaseinhibitorer
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DK1487805T3 (da) Pyrimidinderivater
DE602004012154D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
ATE512960T1 (de) Pyrimidinderivate
DK1544379T3 (da) Klemindretning
DE502004002049D1 (de) Halteeinrichtung
NO20055023D0 (no) Hurtigskytende vapen
DE112004001801D2 (de) Haltevorrichtung
FI5917U1 (fi) Pidin
ES1059189Y (es) Bolsillo.
DE602004004185D1 (de) Klammer
ES1058704Y (es) Antirrobo porta-esquies.
ES1058346Y (es) Porta-boligrafos.
ES1053882Y (es) Hamaca colgante.
SE0400584D0 (sv) NNRTI Antivirals II
ITBO20040669A1 (it) Supporto portapane con oliera
SE0301098D0 (sv) Dubbelhållare
SE0400585D0 (sv) NNRTI Antivirals
ITPD20030088A1 (it) Piedino strutturale reggicartello.
AT500805B8 (de) Abstandhalter
FI20040331A0 (fi) Pidike
ITLT20030007A1 (it) Glucoumato di urea